

**Shared decision-making interventions in the choice of antipsychotic prescription in people living with psychosis (SHAPE): protocol for a realist review**

Short title: Shared decision-making in antipsychotic treatment during psychosis

Ita Fitzgerald\*,<sup>1,2</sup> Laura J. Sahm,<sup>2,3</sup> Jo Howe,<sup>4</sup> Ian Maidment,<sup>4</sup> Emma Wallace,<sup>5</sup> Erin K. Crowley

2

<sup>1</sup>Pharmacy Department, St Patrick's Mental Health Services, Dublin, Ireland.

<sup>2</sup>Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, Ireland.

<sup>3</sup>Pharmacy Department, Mercy University Hospital, Cork, Ireland.

<sup>4</sup>School of Pharmacy, College of Health and Life Sciences, Aston University, United Kingdom.

<sup>5</sup>Department of General Practice, School of Medicine, University College Cork, Ireland.

\*Corresponding author

Email: [118226904@uemail.ucc.ie](mailto:118226904@uemail.ucc.ie)/[itafitzgerald@rcsi.ie](mailto:itafitzgerald@rcsi.ie)

# 1 Abstract

2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

Background: Shared decision-making (SDM) has yet to be successfully adopted into routine use in psychiatric settings amongst people living with severe mental illnesses. Suboptimal rates of SDM are particularly prominent amongst patients with psychotic illnesses during antipsychotic treatment choices. Many interventions have been assessed for their efficacy in improving SDM within this context, although results have been variable and inconsistent.

Aims: To generate an in-depth understanding of how, why, for whom, and to what extent interventions facilitating the application of SDM during choice of antipsychotic drug treatment work and the impact of contextual factors on intervention effectiveness.

Methods: This review will use realist review methodology to provide a causal understanding of how and why interventions work when implementing SDM during choice of antipsychotic treatment. The review will take place over five stages; (1) Locating existing theories, (2) Searching for evidence, (3) Selecting articles, (4) Extracting and organising data and (5) Synthesizing evidence and drawing conclusions. An understanding of how and why interventions work will be achieved by developing realist programme theories on intervention effectiveness through iterative literature reviews and engaging with various stakeholder groups, including patient, clinician and carer representatives.

Discussion: This is the first realist review aiming to identify generative mechanisms explaining how and why successful interventions aimed at improving SDM within the parameters outlined work and in which contexts desired outcomes are most likely to be achieved. Review findings will include suggestions for clinicians, policy and decision-makers about the most promising interventions to pursue and their ideal attributes.

## 25 Introduction

26

27 Shared Decision-Making (SDM) is advocated as an ideal model of treatment decision-making in  
28 mental health and is a key component of person-centred care.<sup>[1,2]</sup> SDM is a concept of non-  
29 paternalistic communication between patients and clinicians, and is most commonly defined as a  
30 process in which clinicians and patients work together to select treatments based on clinical  
31 evidence and the patient's informed preferences.<sup>[2]</sup> International mental health policies have  
32 increasingly advocated partnership models of mental health care, including the application of SDM in  
33 treatment decisions.<sup>[1,2,3]</sup> In the treatment of severe mental illnesses, the application of SDM may be  
34 particularly complicated.<sup>[4]</sup> Complexity in the application of the ideas and ideals of SDM may be  
35 particularly prominent in the treatment of schizophrenia and other enduring psychotic illnesses.  
36 During acute psychosis, a patient's decision-making capacity may be impaired to a significant degree,  
37 resulting in specific challenges for clinicians in the implementation of SDM in initial antipsychotic  
38 treatment decisions. Furthermore, the possibility of involuntary admission for treatment can create  
39 extreme forms of 'power asymmetry' and the importance of long-term antipsychotic adherence  
40 requires special attention to patient satisfaction with treatment.<sup>[4]</sup>

41

42 The principles of SDM may, however, be particularly well-suited to the selection of antipsychotic drug  
43 treatment, an integral component of psychosis management.<sup>[5]</sup> Antipsychotic choice is considered  
44 largely a preference-sensitive decision,<sup>[5,6]</sup> where differences between antipsychotics primarily centre  
45 on differences in side effects rather than efficacy.<sup>[7]</sup> In such cases, choice of antipsychotic treatment is  
46 significantly influenced by the individual's preferences for likely side effects.<sup>[6]</sup> Such preference-  
47 sensitive decisions have been identified as an ideal target for SDM.<sup>[6,8]</sup> Research has shown that the  
48 practice of SDM is highly acceptable amongst patients with enduring psychotic illnesses and  
49 psychiatrists,<sup>[9,10,11]</sup> although differences in attitudes towards and subsequent participation in SDM  
50 have been identified in the case of the latter.<sup>[12]</sup> However, the practice of SDM has yet to be

51 successfully adopted for routine use in psychiatric settings amongst patients with severe mental  
52 illnesses.<sup>[13]</sup> Suboptimal rates of SDM adoption are particularly prominent during antipsychotic  
53 treatment decisions amongst patients with psychotic illnesses.<sup>[12,14,15]</sup> Suggested reasons for low  
54 adoption rates of SDM in these contexts include clinicians' belief that patients with psychosis have  
55 low decisional capacity and cognitive (poor attention, deficits in working memory and verbal fluency)  
56 and motivational deficits.<sup>[11,16]</sup>

57

58 Studies assessing varying interventions aimed at improving the application of SDM in choice of  
59 antipsychotic treatment during psychosis have been undertaken.<sup>[2]</sup> Interventions have largely been  
60 modelled on the application of SDM models in somatic medicine, with additional design features to  
61 account for implementation within psychiatric settings.<sup>[4]</sup> Interventions assessed typically include a  
62 combination of decision aids,<sup>[17,18]</sup> educational interventions for patients and/or clinicians,<sup>[14]</sup> and  
63 digital support tools. <sup>[19,20,21]</sup> To date, the effect size of studied interventions has proven variable and  
64 inconsistent <sup>[2,22]</sup> and positive results are generally smaller than in somatic medicine.<sup>[4,22,23]</sup> Reasons  
65 for varying results, including an understanding of which elements of efficacious interventions are  
66 hypothesized to be responsible for results and how they produced their effects, are largely missing  
67 from the literature. An understanding of these mechanisms is important to support increased and  
68 standardised application of SDM in antipsychotic treatment decisions.

69

70 As highlighted, applying SDM in choice of antipsychotic treatment during psychosis is associated with  
71 significantly more complexity than in somatic medicine.<sup>[13]</sup> Interventions are also expected to be  
72 embedded within existing complex environments and within systems which have traditionally used  
73 paternalistic, clinician-led decision making.<sup>[1,24]</sup> Refinements and adaptations of traditional SDM  
74 models, in general and for local contexts, are likely needed to improve effectiveness, including  
75 consideration of contextual factors relating to patients, clinicians, and the clinical encounter.<sup>[14]</sup>  
76 Although information exchange is an essential element in facilitating SDM,<sup>[24]</sup> the neglect of wider

77 structural and contextual factors in the design and implementation of SDM in choice of antipsychotic  
78 treatment may be one reason for varying results and suboptimal implementation of SDM  
79 interventions.<sup>[1,15]</sup> Thus, uncertainty exists about which intervention types to preferentially  
80 implement, characteristics of interventions to improve the likelihood of achieving desirable  
81 outcomes and the impact of different contexts on intervention effectiveness.

82

83 Any review that seeks to understand SDM interventions, including how they produce their effects,  
84 needs to look beyond the intervention and seek to make sense of the wider context. This need to  
85 account for context and to address questions of how and why interventions work provides the  
86 rationale for using realist review methods in this evidence synthesis.<sup>[25]</sup> Realist reviews aim to move  
87 from empirical observation to developing theoretical causal explanations to understand what it is  
88 about interventions that generate change (i.e., the mechanisms), and under what circumstances the  
89 mechanisms are triggered (i.e., the contexts), which result in changes in behaviour of the participants  
90 of the intervention (i.e., the outcome).<sup>[26]</sup> These three elements i.e., context, mechanism, and  
91 outcome configurations (CMOC), are presented together as a programme theory which attempts to  
92 describe what needs to happen for the intervention to work. A realist approach to evidence synthesis  
93 offers distinctive strengths in addressing questions of what works, for whom, under what  
94 circumstances and how when attempting to develop complex interventions where generated  
95 outcomes are likely variable and context-dependent.<sup>[27]</sup>

96

## 97 **Aims and objectives**

98

99 This realist review aims to understand how interventions designed to improve SDM during  
100 antipsychotic treatment choices work and the impact of contextual factors on intervention success.

101

102 Review objectives include:

- 103 (i) Review the literature to identify what interventions have been studied in improving SDM  
104 in antipsychotic treatment choices (e.g., choice of initial antipsychotic treatment, change  
105 of treatment, or continuation of initial treatment) amongst patients with a psychotic  
106 illness where SDM in the clinical context is preferred.
- 107 (ii) Apply a realist logic of analysis to the literature to understand how and why  
108 interventions have or have not achieved their desired outcomes.
- 109 (iii) Engage with key stakeholders including prescribers and clinicians/practitioners who  
110 support prescribing (pharmacists, nurses, social workers), patients, carers and family  
111 members to identify problems in engaging in SDM within the context outlined.
- 112 (iv) Synthesize the findings into a realist programme theory outlining context-mechanism-  
113 outcome configurations to explain intervention effectiveness.
- 114 (v) Provide recommendations on co-creating, tailoring, and implementing interventions to  
115 improve SDM during antipsychotic treatment choices in patients with a psychotic illness.

116

## 117 **Methods**

118

119 Realist And Meta-narrative Evidence Synthesis: Evolving Standards (RAMESES) guidance will be  
120 followed throughout the review process.<sup>[28]</sup> While this review will be conducted and reported  
121 according to RAMESES standards for realist syntheses, the research team have also populated the  
122 PRISMA-P checklist to provide additional oversight in the methodology of this review (see  
123 supplementary file 1). The review protocol has been registered with PROSPERO (CRD42023443783)  
124 on the 13/10/23 prior to review commencement. The review will follow five iterative stages based on  
125 Pawson's realist methodology, although the process of moving through the steps will proceed in a  
126 non-linear fashion <sup>[26,29,30]</sup> Figure 1 provides an overview of the five steps to be applied in this  
127 review.<sup>[31]</sup>




Figure 1 – Project flow diagram. \* Movement between steps if necessary to further refine programme theory. Adapted from review by Duddy et al.<sup>31</sup>

## 130 Step 1: Locate existing theories

131

132 The rationale of this step is to identify a range of possible theories that explain how interventions  
133 aimed at improving SDM in decisions of antipsychotic treatment are supposed to work (and for  
134 whom), when they do work (or do not) and why they are not being used.<sup>[25]</sup> To locate these theories,  
135 we will (1) perform exploratory literature searches and (2) consult with members of the project team  
136 and stakeholder groups and draw on their experiential, professional and content knowledge. The  
137 project team represents multi- and inter-disciplinary professionals within psychiatry, academia and  
138 those with experience in education and clinical training. This step is more exploratory and aimed at  
139 quickly identifying the range of possible explanatory theories that may be relevant to the review  
140 question.<sup>[25]</sup> For this step, PubMed/MEDLINE, PsycINFO and Open Grey will be used.<sup>[32]</sup>

141

142 Following these searches and discussions with stakeholder groups, iterative discussions within the  
143 project team will be held to interpret and synthesize the different theories into an initial, coherent  
144 programme theory. Meetings of the project team and stakeholder groups will be held online via  
145 Microsoft Teams. Discussion may also be held via telephone calls and e-mail exchange. Detailed  
146 notes of all meetings will be kept to support programme theory development and refinement and to  
147 serve as a clear audit trail. From these processes, an initial programme theory for subsequent testing  
148 in the review will be developed.

149

## 150 Stakeholder group – clinicians/practitioners

151

152 The clinician and practitioner stakeholder group will include representation from consultant  
153 psychiatrists, non-consultant psychiatric doctors, psychiatric nursing, psychiatric pharmacy, general  
154 practitioners and community pharmacy. We aim to identify 12-20 members will be identified through  
155 places of work, partnership organisations and through contacts of the project team. We will extend  
156 the membership as needed for testing of the emerging programme theory.



## 157 Stakeholder group – service users, informal and formal carer givers

158

159 Those with lived experience of psychosis and taking antipsychotic medications will be identified

160 within via the Service User Advisory Network in St Patrick’s Mental Health Services (SPMHS), Dublin,

161 Ireland. Carers will be identified via the Family Members, Carers and Supporters Advisory Network in

162 SPMHS. Both are established patient and carer stakeholder groups which afford local researchers the

163 opportunity to set up advisory or consultation groups specific to the research project. We will also

164 contact local charitable or public engagement organisations to recruit a diverse stakeholder group, if

165 required. We aim to recruit 8-12 people across both cohorts.

166

## 167 Step 2 - Searching for evidence

168

169 The purpose of this step is to find a relevant body of literature with which to further develop and

170 refine the emerging programme theory formed in Step 1.<sup>[26]</sup> Further programme theory refinement

171 will use secondary data identified via formal literature searches.<sup>[33]</sup> Once the initial programme

172 theory has been developed as per Step 1, we will then be able develop the search strategy in full, as

173 in other reviews.<sup>[25,33,34]</sup> For all searches, searching will be designed, piloted and conducted by one

174 researcher (IF) with support from the project team and an academic librarian. We plan to conduct

175 iterative searches of the literature with different search term concepts and permutations to capture

176 the most relevant data relating to the emerging programme theory and any additional research that

177 may add to the conceptual and contextual richness of the studies.<sup>[33]</sup> Modification of the search

178 strategy including terms searched, inclusion and exclusion criteria and databases used may be

179 undertaken depending on the emerging programme theory. The proposed initial sampling frame to

180 be used as the basis for the comprehensive literature search is outlined in Table 1.

181

182

183

184 Table 1 – Overview of inclusion and exclusion criteria.

<p>Population</p>	<p>Include:</p> <ul style="list-style-type: none"> <li>• Adult participants (aged 18-65) experiencing an episode of psychosis in the context of a psychotic illness where extended antipsychotic treatment is indicated.</li> </ul> <p>Exclude:</p> <ul style="list-style-type: none"> <li>• Participants with treatment-resistant schizophrenia due to existence of clozapine as a preferred treatment choice amongst this cohort.</li> <li>• Participants experiencing substance/medication-induced psychosis or psychosis in the context of a general medical condition.</li> </ul>
<p>Intervention</p>	<p>Any intervention designed to facilitate SDM between clinicians and patients in decisions of antipsychotic treatment as part of psychosis management.</p> <p>Given the role of collaborative goal setting and action planning in SDM in long-term conditions,<sup>[35]</sup> alongside internalised stigma that can exist amongst those with mental illnesses,<sup>[36]</sup> we will also include interventions that consist of SDM educational or training programmes for either patients and/or clinicians.</p>
<p>Comparator</p>	<p>Not applicable</p>
<p>Outcome</p>	<p>Outcomes of SDM processes have been assessed in a variety of different ways, relating to both process and outcome measurements.<sup>[2]</sup> This review will include outcomes relating to evidence of SDM application, including improved level of patient and clinician involvement in the decision-making process. Patient perceived involvement in decision-making can be assessed via many ways,<sup>[2]</sup> for example the Shared-Decision Making Questionnaire (SDM-Q-9), the CollaboRATE scale or the Perceived Involvement in Care Scale (PICS).<sup>[37]</sup></p> <p>Other eligible outcomes relating to improving the likelihood of patient engagement in SDM specific to mental health settings,<sup>[38]</sup> including patient-reported improved knowledge, empowerment, self-determination and satisfaction with treatment, will also be considered.</p> <p>Other unanticipated outcomes may also be included in the review. For example, measures of patient satisfaction with care or quality of life measures may be relevant.</p>

	<p>If SDM outcome assessment includes clinical outcomes, for example, improved adherence or reduced hospitalisation, these studies will also be included.</p> <p>Outcomes also relating to physicians perceived involvement in SDM practices will be included, assessed, for example using the physician version of the SDM-Q-9-Doc.<sup>[39]</sup></p>
Timing	Use of interventions to inform choice of antipsychotic treatment (including initial treatment, change of treatment or continuation of treatment) as part of acute psychosis management.
Setting	<p>Inpatient and outpatient settings, including community mental health teams and primary care settings to account for differing designs of mental health services internationally in the management of psychosis.</p> <p>Forensic settings will be excluded.</p> <p>The need for different programme theories for different settings will be considered by the research team.</p>

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

Based on discussion with an academic librarian, we anticipate that we may need to search the following bibliographic databases: PubMed/MEDLINE, Embase, PsycINFO, CINAHL, the Cochrane library, Web of Science, Scopus and Sociological Abstracts. Additional searches for grey literature may be undertaken if required for programme theory refinement using bibliographic databases Open Grey, ProQuest Dissertations, ResearchGate, Google Scholar, and Theses and DART-Europe-E-theses Portal. A combination of free-text and indexing search terms will be selected and adapted for the database being searched. There will be no restrictions on study type. Given the range of conceptual definitions of ‘shared decision-making’ and associated terminology, and the majority of research in this area being conducted amongst participants with schizophrenia,<sup>[6,18,40]</sup> we will structure the search strategy according to schizophrenia and psychotic illness search terms and shared decision-making terms, with the later derived from work conducted by Makoul et al.<sup>[41]</sup> Alerts for new articles which fit the search terms applied will be set to facilitate timely addition of new relevant articles during programme theory development. Only English language studies will be included due to study

200 resources. A date restriction of 1990 to present will be applied. This reflects the timeline over which  
201 person-centred and recovery-focussed care in mental health became the dominant paradigms and  
202 associated application of SDM became advocated as the ideal model of treatment decision-  
203 making.<sup>[1,2]</sup>

204

205 Database searching will be supplemented by additional search methods. We will conduct backwards  
206 and forwards citation searching using Web of Science. We will also use 'cluster searching'  
207 techniques.<sup>[33]</sup> This includes 'sibling' (i.e. directly linked outputs from a single study) and 'kinship' (i.e.  
208 associated papers with a shared contextual or conceptual pedigree) papers.<sup>[33,42]</sup> We will liaise with  
209 members of our stakeholder groups and additional links amongst the project team to recommend  
210 any potentially relevant documents. Searching will continue until sufficient data is found ('theoretical  
211 saturation') to conclude that the refined programme theory or theories are sufficiently coherent and  
212 plausible.<sup>[26]</sup> If the volume of the literature retrieved proves excessive, a variety of appropriate  
213 sampling strategies will be used (e.g. theoretical sampling, maximum variation sampling) to ensure  
214 that we have sufficiently focussed but relevant data for programme theory development.<sup>[26,33]</sup>

215

216 The results of all searches will be exported to Covidence systematic review software. Covidence is a  
217 web-based collaboration software platform that streamlines the production of systematic and other  
218 literature reviews (Covidence systematic review software, Veritas Health Innovation, Melbourne,  
219 Australia; see <http://www.covidence.org>). Following duplicate removal, screening of titles, abstracts  
220 and keywords of potentially relevant articles will be undertaken by one member of the research  
221 team (IF). A 10% random subsample of all studies will be reviewed independently by another  
222 researcher (LS/EC/IM/JH/EW) against the inclusion criteria for any systematic errors. Inclusion and  
223 exclusion criteria will be finalised by the project team following Step 1. Disagreements will be  
224 resolved by discussion and recourse to an independent member of the project team until consensus  
225 is achieved.<sup>[32]</sup>

### 226 Step 3: Selecting articles

227

228 Screening of full-text articles identified for potential inclusion will be undertaken by one researcher  
229 (IF). Covidence software will also be used for this step. The selection of articles for final inclusion will  
230 primarily focus on relevance (whether data could contribute to some aspect of the testing and  
231 advancement of the programme theory) and rigour (whether the methods used to generate the  
232 relevant data are credible and trustworthy to warrant making changes to the programme  
233 theory).<sup>[32,33]</sup> As in other studies,<sup>[25,33,34]</sup> to illustrate how we will operationalise rigour, if data relevant  
234 to an aspect of the programme theory have been generated using a questionnaire for example, then  
235 the trustworthiness of the data would be greater if the tool used had been tested and demonstrated  
236 as a valid and reliable measure of the phenomenon being assessed.<sup>[25]</sup> An overall assessment of the  
237 rigour at the level of the programme theory will also be made.<sup>[33]</sup>

238

239 One researcher (IF) will read all included papers and include documents or studies that contain data  
240 relevant to the realist analysis i.e., could inform some aspect of the programme theory. Reasons for  
241 exclusion of each study will be noted, for example if records are classified by the research team as  
242 having low relevance to the programme theory. For those articles deemed to meet the inclusion  
243 criteria, IF will retrieve the full text and classify studies into high and low relevance, depending on  
244 their relevance to the programme theory, and based on established methods previously  
245 employed.<sup>[32,43,44]</sup> A random subsample of the 10% of final documents for inclusion will be selected  
246 and assessed independently by another member of the research team (LS/EC/IM/JH/EW) to identify  
247 systematic errors.<sup>[26, 33]</sup> The remaining 90% of decisions will be made by IF, although a number of  
248 these may require further discussion/joint reading between the wider project team due to issues of  
249 uncertainty regarding relevance and/or rigour. Discussions will continue until consensus is reached.

250

251

## 252 Step 4: Extracting and organising data

253

254 Data extraction and organisation will be undertaken by one researcher (IF) using Microsoft Excel.

255 Study characteristics to be extracted include:

256 • Study details (publication year, location of study)

257 • Study objectives

258 • Intervention description

259 • Study design and quality markers (rigour, relevance)

260 • Study methods

261 • Sample characteristics (age, gender, ethnicity)

262 • Contextual factors (mechanisms) before the intervention was introduced

263 • Outcomes and how they were measured

264

265 The full texts of all included papers will be uploaded to NVivo qualitative data analysis software.

266 Documents will be examined for data on how SDM interventions work by applying a realist logic of

267 analysis to relevant sections of the text. The synthesis of evidence will begin with conceptual coding.

268 Sections of text will be coded in broad conceptual categories ('conceptual buckets') for example,

269 developing therapeutic alliance, adequate information sources, beginning with the richest sources

270 i.e. articles with the most potential to inform the programme theory. As the review progresses,

271 these conceptual codes will be analysed to develop context-mechanism-outcome configurations

272 (CMOC).<sup>[45]</sup> Allocation of codes will be both inductive and deductive. Retroductive coding will also be

273 applied i.e. where codes are created based on an interpretation of data to infer potential hidden

274 causal mechanisms for outcomes.<sup>[33]</sup>

275

276 Each new element of coded data will be used to refine the programme theory, as appropriate. As the

277 theory is refined, included studies will be re-scrutinised for data relevant to the revised theory that

278 may have been missed initially.<sup>[32]</sup> This step will initially be completed by one researcher (IF) with

279 support from other members of the team experienced in realist methodology (JH/IM). The project  
280 team will examine the viability of different CMOCs, experiment with varying formulations and work  
281 towards building the narrative of the evidence synthesis.<sup>[32]</sup> The developing programme theory will  
282 be confirmed with the rest of the project team iteratively and at defined stages. In the case of data  
283 extraction and coding of papers, a 10% random subsample of papers will be reviewed independently  
284 by other members of the research team (EW/LS/IM/JH/EC) as part of quality control measures. Any  
285 disagreements will be resolved via discussion until consensus is achieved.

286

## 287 **Step 5: Synthesising the evidence and drawing conclusions**

288

289 To develop the final programme theory, we will move iteratively between the analysis of certain  
290 sections of included papers, stakeholder group interpretation and further iterative searching for data  
291 in the included studies to refine the programme theory and its subsections. The purpose of this step  
292 is to understand how mechanisms behave under the different contexts described within the review  
293 documents.<sup>[25]</sup> We will move from data to theory to refine explanations about why certain  
294 interventions are effective (or not). This will include inferences about which mechanisms may be  
295 triggered in specific circumstances and contexts, as these are likely to be hidden and not explicitly or  
296 adequately referred to in the literature. Relationships between context, mechanism and outcomes  
297 will be sought across articles included.<sup>[32]</sup> In keeping with the application of a realist logic of analysis,  
298 a series of questions will be used to support the analysis and synthesis of data including: <sup>[33,26]</sup>

- 299 • Interpretation of meaning: if relevant and trustworthy, do the contents of the included  
300 document provide data that may be interpreted as functioning as context, mechanism or  
301 outcome?
- 302 • Interpretation and judgements about CMOCs: For example, what is the CMOC (partial or  
303 complete) for the data that has been interpreted as functioning as context, mechanism, or  
304 outcome? Are there further data to inform this particular CMOC contained within this source  
305 or other sources?

306 • Interpretations and judgements about programme theory: For example, how does this (full  
307 or partial) CMOC relate to the programme theory under development? Within the same  
308 document, are there data which informs how the CMOC relates to the programme theory?  
309 When working through these questions, where appropriate, we will apply the following forms of  
310 reasoning to make sense of the data: juxtaposition of the data, reconciliation of the data,  
311 adjudication of the data and consolidation of the data.<sup>[32,33]</sup> All members of the project team will be  
312 involved in generation of the final programme theory/theories.

313

## 314 Ethics

315

316 Primary data will not be collected and therefore, ethical approval is not required for this review.

317

## 318 Discussion

319

### 320 Novelty of the review

321

322 This review will be the first realist review of the literature examining interventions aimed at

323 improving SDM application during antipsychotic treatment choices amongst those with an enduring

324 psychotic illness. The review will blend empirical research with the views, experience, and expertise

325 of people with lived experience of psychosis, professionals and practitioners in this field, academics

326 and topic experts. Systematic review findings suggest that several interventions are helpful in

327 promoting the application of SDM within this context.<sup>[2]</sup> The literature has, however, focused on the

328 effectiveness and impact of interventions, without considering underlying processes and contextual

329 influences. There is a need for further evidence on how interventions work, for whom and under

330 what circumstances to understand what can be done to maximise their chances of success. The

331 review aims to identify those generative mechanisms underlying effective interventions and in which

332 contexts are the desired outcomes most likely to be achieved. The findings of the review will enable



333 us to provide suggestions for clinicians, policy and decision-makers about the most promising  
334 interventions to pursue and their ideal attributes, and what refinements are needed for local  
335 tailoring and implementation.

336

## 337 **Impact and dissemination**

338

339 Review results will be used to inform future policy, research and practice in in this area. The research

340 team will share findings through their networks and promote change beyond the end of the project.

341 The findings of this realist review will also be made public through a peer-reviewed open access

342 publication. Findings will be disseminated and shared through knowledge exchange with

343 stakeholders and policymakers at a national and international level via conferences and personal

344 communication. Key stakeholders within the project and wider team (including stakeholder groups)

345 will be consulted to disseminate findings through their local and national networks. To increase the

346 accessibility of the review findings, user-friendly summaries will be produced and tailored suitable

347 for healthcare professionals, service users and their families. Use of social media platforms will be

348 considered to increase engagement from the wider population.

349 **Acknowledgements:** We would like to thank academic librarian Virginia Conrick for her assistance in  
350 the preparation of search strategy for this review.

351

## 352 **References**

- 353 1. Slade M. Implementing shared decision making in routine mental health care. *World Psychiatry*  
354 2017;**16**(2): 146–53.
- 355 2. Aoki Y, Yaju Y, Utsumi T, Sanyaolu L, Storm M, Takaesu Y, et al. Shared decision-making  
356 interventions for people with mental health conditions. *Cochrane Database Syst Rev* 2022; **11**.  
357 Available from: <https://doi.org/10.1002/14651858.CD007297.pub3>.
- 358 3. NICE. Overview | Service user experience in adult mental health: improving the experience of  
359 care for people using adult NHS mental health services. 2011 [cited August 2023]. Available  
360 from: <https://www.nice.org.uk/guidance/cg136>
- 361 4. Beitinger R, Kissling W, Hamann J. Trends and perspectives of shared decision-making in  
362 schizophrenia and related disorders. *Curr Opin Psychiatry* 2014;**27**(3): 222-229.
- 363 5. NICE. Recommendations | Psychosis and schizophrenia in adults: prevention and management  
364 | Guidance. 2014 [cited March 2023]. Available from:  
365 <https://www.nice.org.uk/guidance/cg178/chapter/Recommendations>
- 366 6. Müller K, Schuster F, Rodolico A, Siafis S, Leucht S, Hamann J. How should patient decision aids  
367 for schizophrenia treatment be designed? - A scoping review. *Schizophr Res* 2023;**255**: 261–73.
- 368 7. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al.  
369 Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults  
370 with multi-episode schizophrenia: a systematic review and network meta-analysis. *The Lancet*  
371 2019;**14**(394): 939-951.
- 372 8. Morant N, Kaminskiy E, Ramon S. Shared decision making for psychiatric medication  
373 management: beyond the micro-social. *Health Expect* 2016; **19**(5): 1002–14.
- 374 9. Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Do patients with schizophrenia wish to be  
375 involved in decisions about their medical treatment? *Am J Psychiatry* 2005;**162**(12): 2382–4.
- 376 10. Seale C, Chaplin R, Lelliott P, Quirk A. Sharing decisions in consultations involving anti-psychotic  
377 medication: a qualitative study of psychiatrists' experiences. *Soc Sci Med* 2006;**62**(11): 2861–  
378 73.
- 379 11. Hamann J, Mendel R, Cohen R, Heres S, Ziegler M, Bühner M, et al. Psychiatrists' Use of Shared  
380 Decision Making in the Treatment of Schizophrenia: Patient Characteristics and Decision Topics.  
381 *Psychiatr Serv* 2009;**60**(8): 1107–12.
- 382 12. Haugom EW, Stensrud B, Beston G, Ruud T, Landheim AS. Experiences of shared decision  
383 making among patients with psychotic disorders in Norway: a qualitative study. *BMC Psychiatry*  
384 2022;**22**(1):192. Available from: <https://doi:10.1186/s12888-022-03849-8>.

- 385 13. Zisman-Ilani Y, Roth RM, Mistler LA. Time to Support Extensive Implementation of Shared  
386 Decision Making in Psychiatry. *JAMA Psychiatry* 2021;**78**(11):1183–4.
- 387 14. Hamann J, Holzhüter F, Blakaj S, Becher S, Haller B, Landgrebe M, et al. Implementing shared  
388 decision-making on acute psychiatric wards: a cluster-randomized trial with inpatients suffering  
389 from schizophrenia (SDM-PLUS). *Epidemiol Psychiatr Sci* 2020; **16**(29):e137. Available from:  
390 <https://doi.org/10.1017/S2045796020000505>.
- 391 15. Grunwald LM, Thompson J. Re-starting the conversation: improving shared decision making in  
392 antipsychotic prescribing. *Psychosis* 2021;**13**(4): 373-377.
- 393 16. Larkin A, Hutton P. Systematic review and meta-analysis of factors that help or hinder  
394 treatment decision-making capacity in psychosis. *Br J Psychiatry* 2017;**211**(4): 205–15.
- 395 17. Hamann J, Langer B, Winkler V, Busch R, Cohen R, Leucht S, et al. Shared decision making for in-  
396 patients with schizophrenia. *Acta Psychiatr Scand* 2006;**114**(4):265–73.
- 397 18. Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Shared decision making and long-term  
398 outcome in schizophrenia treatment. *J Clin Psychiatry* 2007;**68**(7):992–7.
- 399 19. Vitger T, Hjorthøj C, Austin SF, Petersen L, Tønder ES, Nordentoft M, et al. A Smartphone App to  
400 Promote Patient Activation and Support Shared Decision-making in People With a Diagnosis of  
401 Schizophrenia in Outpatient Treatment Settings (Momentum Trial): Randomized Controlled  
402 Assessor-Blinded Trial. *J Med Internet Res* 2022;**26**;24(10):e40292. Available from:  
403 <https://doi.org/10.2196/40292>.
- 404 20. Mueser KT, Penn DL, Addington J, Brunette MF, Gingerich S, Glynn SM, et al. The NAVIGATE  
405 Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial  
406 Components. *Psychiatr Serv* 2015;**66**(7): 680–90.
- 407 21. Tasma M, Roebroek LO, Liemburg EJ, Knegtering H, Delespaul PA, Boonstra A, et al. The  
408 development and evaluation of a computerized decision aid for the treatment of psychotic  
409 disorders. *BMC Psychiatry* 2018;**18**(1): Available from: <https://doi.org/10.1186/s12888-018-1750-7>.
- 410 22. Chmielowska M, Zisman-Ilani Y, Saunders R, Pilling S. Trends, challenges, and priorities for  
411 shared decision making in mental health: The first umbrella review. *Int J Soc Psychiatry*  
412 2023;**69**(4): 823-840
- 413 23. Keij SM, Boer JE de, Stiggelbout AM, Bruin WB de, Peters E, Moaddine S, et al. How are patient-  
414 related characteristics associated with shared decision-making about treatment? A scoping  
415 review of quantitative studies. *BMJ Open* 2022;**12**(5):e057293. Available from:  
416 <https://bmjopen.bmj.com/content/12/5/e057293>
- 417 24. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it  
418 mean? (or it takes at least two to tango). *Soc Sci Med* 1997;**44**(5):681–92.
- 419 25. Wong G, Brennan N, Mattick K, Pearson M, Briscoe S, Papoutsi C. Interventions to improve  
420 antimicrobial prescribing of doctors in training: the IMPACT (IMProving Antimicrobial  
421 presCribing of doctors in Training) realist review. *BMJ Open* 2015;**5**(10):e009059. Available  
422 from: <https://doi.org/10.1136/bmjopen-2015-009059>
- 423 26. Wong G, Greenhalgh T, Westhorp G, Pawson R. Development of methodological guidance,  
424 publication standards and training materials for realist and meta-narrative reviews: the

- 425 RAMESES (Realist And Meta-narrative Evidence Syntheses – Evolving Standards) project  
 426 [Internet]. Southampton (UK): NIHR Journals Library; 2014 [cited 2023 Mar 31]. (Health  
 427 Services and Delivery Research). Available from:  
 428 <http://www.ncbi.nlm.nih.gov/books/NBK260013/>
- 429 27. Duddy C, Wong G. Grand rounds in methodology: when are realist reviews useful, and what  
 430 does a ‘good’ realist review look like? *BMJ Qual Saf* 2023;**32**(3):173–80.
- 431 28. Greenhalgh T, Wong G, Westhorp G, Pawson R. Protocol - realist and meta-narrative evidence  
 432 synthesis: Evolving Standards (RAMESES). *BMC Med Res Methodol* 2011;**11**. Available from:  
 433 <https://doi.org/10.1186/1471-2288-11-115>
- 434 29. Wong G. REALIST REVIEWS IN HEALTH POLICY AND SYSTEMS RESEARCH [Internet]. Evidence  
 435 Synthesis for Health Policy and Systems: A Methods Guide. World Health Organization; 2018  
 436 [cited 2023 Feb 26]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK569577/>
- 437 30. Saul JE, Willis CD, Bitz J, Best A. A time-responsive tool for informing policy making: rapid realist  
 438 review. *Implement Sci* 2013;**8**(1):103.
- 439 31. Duddy C, Wong G, Gadsby EW, Krska J, Hibberd V. NHS Health Check programme: a protocol for  
 440 a realist review. *BMJ Open* 2021;**11**(4):e048937. Available at: [http://doi: 10.1136/bmjopen-](http://doi: 10.1136/bmjopen-2021-048937)  
 441 [2021-048937](http://doi: 10.1136/bmjopen-2021-048937).
- 442 32. Papoutsis C, Mattick K, Pearson M, Brennan N, Briscoe S, Wong G. Social and professional  
 443 influences on antimicrobial prescribing for doctors-in-training: a realist review. *J Antimicrob*  
 444 *Chemother* 2017;**72**(9):2418–30.
- 445 33. Maidment I, Wong G, Duddy C, Upthegrove R, Oduola S, Allen K, et al. Medication optimisation  
 446 in severe mental illness (MEDIATE): protocol for a realist review. *BMJ Open*  
 447 2022;**12**(1):e058524. Available from: <https://bmjopen.bmj.com/content/12/1/e058524>
- 448 34. Maidment ID, Wong G, Duddy C, Upthegrove R, Oduola S, Robotham D, et al. REalist Synthesis  
 449 Of non-pharmacological interVEntions for antipsychotic-induced weight gain (RESOLVE) in  
 450 people living with severe mental illness (SMI). *Syst Rev* 2022;**11**(1):42. Available from:  
 451 <https://doi.org/10.1186/s13643-022-01912-9>
- 452 35. Coulter A, Entwistle VA, Eccles A, Ryan S, Shepperd S, Perera R. Personalised care planning for  
 453 adults with chronic or long-term health conditions. *Cochrane Database Syst Rev* 2015  
 454 ;2015(3):CD010523. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486144/>
- 455 36. Drapalski AL, Lucksted A, Perrin PB, Aakre JM, Brown CH, DeForge BR, et al. A Model of  
 456 Internalized Stigma and Its Effects on People With Mental Illness. *Psychiatr Serv*  
 457 2013;**64**(3):264–9.
- 458 37. Ubbink DT, van Asbeck EV, Aarts JWM, Stubenrouch FE, Geerts PAF, Atsma F, et al. Comparison  
 459 of the CollaboRATE and SDM-Q-9 questionnaires to appreciate the patient-reported level of  
 460 shared decision-making. *Patient Educ Couns*. 2022;**105**(7): 2475–9.
- 461 38. Zisman-Ilani Y, Chmielowska M, Dixon LB, Ramon S. NICE shared decision making guidelines and  
 462 mental health: challenges for research, practice and implementation. *BJPsych Open*  
 463 2021;**7**(5):e154. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444056/>

- 464 39. Scholl I, Kriston L, Dirmaier J, Buchholz A, Härter M. Development and psychometric properties  
465 of the Shared Decision Making Questionnaire--physician version (SDM-Q-Doc). *Patient Educ*  
466 *Couns* 2012;**88**(2):284–90.
- 467 40. Siafis S, Bursch N, Müller K, Schmid L, Schuster F, Waibel J, et al. Evidence-based Shared-  
468 Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-  
469 randomized trial in hospitalized patients with schizophrenia. *BMC Psychiatry* 2022;**22**(1):406.
- 470 41. Makoul G, Clayman ML. An integrative model of shared decision making in medical encounters.  
471 *Patient Educ Couns* 2006;**60**(3): 301–12.
- 472 42. Booth A, Harris J, Croot E, Springett J, Campbell F, Wilkins E. Towards a methodology for cluster  
473 searching to provide conceptual and contextual “richness” for systematic reviews of complex  
474 interventions: case study (CLUSTER). *BMC Med Res Methodol* 2013;**13**(1):118. Available from:  
475 <https://doi.org/10.1186/1471-2288-13-118>
- 476 43. Howe J, MacPhee M, Duddy C, Habib H, Wong G, Jacklin S, et al. A realist review of medication  
477 optimisation of community dwelling service users with serious mental illness. *medRxiv*  
478 *[preprint]* 2023. Available from:  
479 <https://www.medrxiv.org/content/10.1101/2023.08.02.23293542v1>
- 480 44. Dada S, Dalkin S, Gilmore B, Hunter R, Mukumbang FC. Applying and reporting relevance,  
481 richness and rigour in realist evidence appraisals: Advancing key concepts in realist reviews. *Res*  
482 *Synth Methods* 2023;**14**(3): 504–14.
- 483 45. Price T, Brennan N, Cleland J, Prescott-Clements L, Wanner A, Withers L, et al. Remediating  
484 doctors’ performance to restore patient safety: a realist review protocol. *BMJ Open* 2018;  
485 **8**(10):e025943. Available from: <https://bmjopen.bmj.com/content/8/10/e025943>
- 486

487 **Author contributions**

488

489 **Conceptualisation:** Ita Fitzgerald, Laura J. Sahm, Erin K. Crowley

490 **Methodology:** Ita Fitzgerald, Ian Maidment, Jo Howe

491 **Project administration:** Ita Fitzgerald, Laura J. Sahm, Jo Howe, Ian Maidment, Emma Wallace, Erin K.

492 Crowley

493 **Writing – original draft:** Ita Fitzgerald, Laura J. Sahm, Erin K. Crowley

494 **Writing – review and editing:** Ita Fitzgerald, Laura J. Sahm, Jo Howe, Ian Maidment, Emma Wallace,

495 Erin K. Crowley

496

497

498

499